Primary Lymphedema

in Lymphedema

Applied

Type

Addition

Confidence

90%

Created

Mar 26, 2026

Evidence

1 source

Rationale

The existing section was limited to the classification and etiology of primary lymphedema. The integration of the 2025 AVF/AVLS position statement adds important clinical management context, specifically regarding the utility of non-pneumatic compression (NPC). Additionally, the abbreviation VEGFR3 was expanded to comply with the textbook's formatting rules for first-use abbreviations.

Evidence

Jacobowitz GR et al. Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41271100.
Verified source
PubMedDOI

Content Changes

* Congenital or genetic defects in lymphatic development.
* **Milroy disease:** congenital, VEGFR3vascular endothelial growth factor receptor 3 (VEGFR3) mutation.
* **Meige disease:** onset around puberty.
* Late-onset primary lymphedema (20–40 yrs).
* Management includes the use of non-pneumatic compression (NPC), which is endorsed for its clinical utility by the American Venous Forum (AVF) and the American Venous and Lymphatic Society (AVLS) [@jacobowitz2025].
Go to section in textbookDispute / Submit evidenceAll updates